Search Results - "Paweletz, Cloud P"

Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies by Odegaard, Justin I, Vincent, John J, Mortimer, Stefanie, Vowles, James V, Ulrich, Bryan C, Banks, Kimberly C, Fairclough, Stephen R, Zill, Oliver A, Sikora, Marcin, Mokhtari, Reza, Abdueva, Diana, Nagy, Rebecca J, Lee, Christine E, Kiedrowski, Lesli A, Paweletz, Cloud P, Eltoukhy, Helmy, Lanman, Richard B, Chudova, Darya I, Talasaz, AmirAli

“…To analytically and clinically validate a circulating cell-free tumor DNA sequencing test for comprehensive tumor genotyping and demonstrate its clinical…”
Get full text

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M by Thress, Kenneth S, Paweletz, Cloud P, Felip, Enriqueta, Cho, Byoung Chul, Stetson, Daniel, Dougherty, Brian, Lai, Zhongwu, Markovets, Aleksandra, Vivancos, Ana, Kuang, Yanan, Ercan, Dalia, Matthews, Sarah E, Cantarini, Mireille, Barrett, J Carl, Jänne, Pasi A, Oxnard, Geoffrey R

“…A mutation conferring resistance to novel irreversible EGFR inhibitors is identified in cell-free plasma DNA from lung cancer patients. Here we studied…”
Get full text

False positive plasma genotyping due to clonal hematopoiesis by Hu, Yuebi, Ulrich, Bryan, Supplee, Julianna, Kuang, Yanan, Lizotte, Patrick H, Feeney, Nora, Guibert, Nicolas, Awad, Mark M, Wong, Kwok-Kin, Janne, Pasi A, Paweletz, Cloud Peter, Oxnard, Geoffrey R

“…Plasma cell-free DNA (cfDNA) genotyping is increasingly used in cancer care, but assay accuracy is debated. Because most cfDNA is derived from peripheral blood…”
Get full text

Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA by OXNARD, Geoffrey R, PAWELETZ, Cloud P, JÄNNE, Pasi A, YANAN KUANG, MACH, Stacy L, O'CONNELL, Allison, MESSINEO, Melissa M, LUKE, Jason J, BUTANEY, Mohit, KIRSCHMEIER, Paul, JACKMAN, David M

“…Tumor genotyping using cell-free plasma DNA (cfDNA) has the potential to allow noninvasive assessment of tumor biology, yet many existing assays are cumbersome…”
Get full text

3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade by Aref, Amir R, Campisi, Marco, Ivanova, Elena, Portell, Andrew, Larios, Dalia, Piel, Brandon P, Mathur, Natasha, Zhou, Chensheng, Coakley, Raven Vlahos, Bartels, Alan, Bowden, Michaela, Herbert, Zach, Hill, Sarah, Gilhooley, Sean, Carter, Jacob, Cañadas, Israel, Thai, Tran C, Kitajima, Shunsuke, Chiono, Valeria, Paweletz, Cloud P, Barbie, David A, Kamm, Roger D, Jenkins, Russell W

“…Microfluidic culture has the potential to revolutionize cancer diagnosis and therapy. Indeed, several microdevices are being developed specifically for…”
Get more information

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients by Paweletz, Cloud P, Sacher, Adrian G, Raymond, Chris K, Alden, Ryan S, O'Connell, Allison, Mach, Stacy L, Kuang, Yanan, Gandhi, Leena, Kirschmeier, Paul, English, Jessie M, Lim, Lee P, Jänne, Pasi A, Oxnard, Geoffrey R

“…Tumor genotyping is a powerful tool for guiding non-small cell lung cancer (NSCLC) care; however, comprehensive tumor genotyping can be logistically…”
Get full text

Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients by Hu, Yuebi, Alden, Ryan S, Odegaard, Justin I, Fairclough, Stephen R, Chen, Ruthia, Heng, Jennifer, Feeney, Nora, Nagy, Rebecca J, Shah, Jayshree, Ulrich, Bryan, Gutierrez, Martin, Lanman, Richard B, Garber, Judy E, Paweletz, Cloud P, Oxnard, Geoffrey R

“…Plasma cell-free DNA (cfDNA) analysis is increasingly used clinically for cancer genotyping, but may lead to incidental identification of germline-risk…”
Get full text

Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade by Rashidian, Mohammad, LaFleur, Martin W., Verschoor, Vincent L., Dongre, Anushka, Zhang, Yun, Nguyen, Thao H., Kolifrath, Stephen, Aref, Amir R., Lau, Christie J., Paweletz, Cloud P., Bu, Xia, Freeman, Gordon J., Barrasaf, M. Inmaculad, Weinberg, Robert A., Sharpe, Arlene H., Ploegh, Hidde L.

“…Immunotherapy using checkpoint-blocking antibodies against PD-1 has produced impressive results in a wide range of cancers. However, the response remains…”
Get full text

Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA by Supplee, Julianna G., Milan, Marina S.D., Lim, Lee P., Potts, Kristy T., Sholl, Lynette M., Oxnard, Geoffrey R., Paweletz, Cloud P.

“…•Next-generation sequencing (NGS) of cell-free DNA could expand access to precision medicine.•Technical differences between plasma NGS assays are poorly…”
Get full text

EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples by Rangachari, Deepa, To, Ciric, Shpilsky, Jason E, VanderLaan, Paul A, Kobayashi, Susumu S, Mushajiang, Mierzhati, Lau, Christie J, Paweletz, Cloud P, Oxnard, Geoffrey R, Jänne, Pasi A, Costa, Daniel B

“…Osimertinib is approved for advanced EGFR-mutated NSCLC, and identification of on-target mechanisms of resistance (i.e., EGFR C797S) to this third-generation…”
Get more information

Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer by Bahcall, Magda, Sim, Taebo, Paweletz, Cloud P, Patel, Jyoti D, Alden, Ryan S, Kuang, Yanan, Sacher, Adrian G, Kim, Nam Doo, Lydon, Christine A, Awad, Mark M, Jaklitsch, Michael T, Sholl, Lynette M, Jänne, Pasi A, Oxnard, Geoffrey R

“…Amplified and/or mutated MET can act as both a primary oncogenic driver and as a promoter of tyrosine kinase inhibitor (TKI) resistance in non-small cell lung…”
Get more information

Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition by Soucheray, Margaret, Capelletti, Marzia, Pulido, Inés, Kuang, Yanan, Paweletz, Cloud P, Becker, Jeffrey H, Kikuchi, Eiki, Xu, Chunxiao, Patel, Tarun B, Al-Shahrour, Fatima, Carretero, Julián, Wong, Kwok-Kin, Jänne, Pasi A, Shapiro, Geoffrey I, Shimamura, Takeshi

“…Non-small cell lung cancers (NSCLC) that have developed resistance to EGF receptor (EGFR) tyrosine kinase inhibitor (TKI), including gefitinib and erlotinib,…”
Get full text

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd by Haikala, Heidi M, Lopez, Timothy, Köhler, Jens, Eser, Pinar O, Xu, Man, Zeng, Qing, Teceno, Tyler J, Ngo, Kenneth, Zhao, Yutong, Ivanova, Elena V, Bertram, Arrien A, Leeper, Brittaney A, Chambers, Emily S, Adeni, Anika E, Taus, Luke J, Kuraguchi, Mari, Kirschmeier, Paul T, Yu, Channing, Shiose, Yoshinobu, Kamai, Yasuki, Qiu, Yang, Paweletz, Cloud P, Gokhale, Prafulla C, Jänne, Pasi A

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are the standard-of-care treatment for -mutant non-small cell lung cancers (NSCLC)…”
Get full text

Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours by Konstantinopoulos, Panagiotis A., Cheng, Su-Chun, Supko, Jeffrey G., Polak, Madeline, Wahner-Hendrickson, Andrea E., Ivy, S. Percy, Bowes, Brittany, Sawyer, Hannah, Basada, Patrice, Hayes, Martin, Curtis, Jennifer, Horowitz, Neil, Wright, Alexi A., Campos, Susana M., Ivanova, Elena V., Paweletz, Cloud P., Palakurthi, Sangeetha, Liu, Joyce F., D’Andrea, Alan D., Gokhale, Prafulla C., Chowdhury, Dipanjan, Matulonis, Ursula A., Shapiro, Geoffrey I.

“…Purpose PARP inhibitor resistance may be overcome by combinatorial strategies with agents that disrupt homologous recombination repair (HRR). Multiple HRR…”
Get full text

Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer by Hanna, Glenn J., Lau, Christie J., Mahmood, Umair, Supplee, Julianna G., Mogili, Abhishek R., Haddad, Robert I., Jänne, Pasi A., Paweletz, Cloud P.

“…•Salivary HPV DNA levels align with local disease burden in HPV oropharyngeal cancer.•The rise and fall of salivary HPV DNA often predicts treatment response…”
Get full text

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer by Bahcall, Magda, Awad, Mark M, Sholl, Lynette M, Wilson, Frederick H, Xu, Man, Wang, Stephen, Palakurthi, Sangeetha, Choi, Jihyun, Ivanova, Elena V, Leonardi, Giulia C, Ulrich, Bryan C, Paweletz, Cloud P, Kirschmeier, Paul T, Watanabe, Masayuki, Baba, Hideo, Nishino, Mizuki, Nagy, Rebecca J, Lanman, Richard B, Capelletti, Marzia, Chambers, Emily S, Redig, Amanda J, VanderLaan, Paul A, Costa, Daniel B, Imamura, Yu, Jänne, Pasi A

“…MET inhibitors can be effective therapies in patients with exon 14 ( ex14) mutant non-small cell lung cancer (NSCLC). However, long-term efficacy is limited by…”
Get full text

Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer by Nardi, Francesca, Perurena, Naiara, Schade, Amy E, Li, Ze-Hua, Ngo, Kenneth, Ivanova, Elena V, Saldanha, Aisha, Li, Chendi, Gokhale, Prafulla C, Hata, Aaron N, Barbie, David A, Paweletz, Cloud P, Jänne, Pasi A, Cichowski, Karen

“…Despite the success of KRAS G12C inhibitors in non-small cell lung cancer (NSCLC), more effective treatments are needed. One preclinical strategy has been to…”
Get full text

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer by Yoshida, Ryohei, Saigi, Maria, Tani, Tetsuo, Springer, Benjamin F, Shibata, Hirofumi, Kitajima, Shunsuke, Mahadevan, Navin R, Campisi, Marco, Kim, William, Kobayashi, Yoshihisa, Thai, Tran C, Haratani, Koji, Yamamoto, Yurie, Sundararaman, Shriram K, Knelson, Erik H, Vajdi, Amir, Canadas, Israel, Uppaluri, Ravindra, Paweletz, Cloud P, Miret, Juan J, Lizotte, Patrick H, Gokhale, Prafulla C, Jänne, Pasi A, Barbie, David A

“…Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been…”
Get full text

Cell-Free DNA in Oncology: Gearing up for Clinic by Ulrich, Bryan C, Paweletz, Cloud P

“…In the past several years, interest in the clinical utility of cell-free DNA as a noninvasive cancer biomarker has grown rapidly. Success in the development of…”
Get full text

Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer by Ivanova, Elena, Kuraguchi, Mari, Xu, Man, Portell, Andrew J, Taus, Luke, Diala, Irmina, Lalani, Alshad S, Choi, Jihyun, Chambers, Emily S, Li, Shuai, Liu, Shengwu, Chen, Ting, Barbie, Thanh U, Oxnard, Geoffrey R, Haworth, Jacob J, Wong, Kwok-Kin, Dahlberg, Suzanne E, Aref, Amir A, Barbie, David A, Bahcall, Magda, Paweletz, Cloud P, Jänne, Pasi A

“…Evaluating drug responses using primary patient-derived cells represents a potentially rapid and efficient approach to screening for new treatment approaches…”
Get full text